CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $398.91 million. The enterprise value is $362.41 million.
Important Dates
The last earnings date was Tuesday, March 25, 2025, before market open.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 65.18 million shares outstanding. The number of shares has increased by 15.66% in one year.
| Current Share Class | 65.18M |
| Shares Outstanding | 65.18M |
| Shares Change (YoY) | +15.66% |
| Shares Change (QoQ) | +4.56% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 36.14% |
| Float | 64.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.14 |
| PS Ratio | 9.13 |
| Forward PS | 2.85 |
| PB Ratio | 5.13 |
| P/TBV Ratio | 4.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.39 |
| Quick Ratio | 3.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -614.10 |
Financial Efficiency
Return on equity (ROE) is -23.17% and return on invested capital (ROIC) is -17.92%.
| Return on Equity (ROE) | -23.17% |
| Return on Assets (ROA) | -13.91% |
| Return on Invested Capital (ROIC) | -17.92% |
| Return on Capital Employed (ROCE) | -26.30% |
| Revenue Per Employee | $523,761 |
| Profits Per Employee | -$216,024 |
| Employee Count | 83 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | -1.39M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.64% in the last 52 weeks. The beta is 1.53, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +47.64% |
| 50-Day Moving Average | 10.35 |
| 200-Day Moving Average | 8.30 |
| Relative Strength Index (RSI) | 23.34 |
| Average Volume (20 Days) | 2,000,653 |
Short Selling Information
The latest short interest is 8.18 million, so 12.55% of the outstanding shares have been sold short.
| Short Interest | 8.18M |
| Short Previous Month | 7.88M |
| Short % of Shares Out | 12.55% |
| Short % of Float | 12.68% |
| Short Ratio (days to cover) | 10.23 |
Income Statement
In the last 12 months, CorMedix had revenue of $43.47 million and -$17.93 million in losses. Loss per share was -$0.30.
| Revenue | 43.47M |
| Gross Profit | 40.28M |
| Operating Income | -22.36M |
| Pretax Income | n/a |
| Net Income | -17.93M |
| EBITDA | -22.05M |
| EBIT | -22.36M |
| Loss Per Share | -$0.30 |
Full Income StatementBalance Sheet
The company has $51.69 million in cash and $517,013 in debt, giving a net cash position of $51.17 million or $0.79 per share.
| Cash & Cash Equivalents | 51.69M |
| Total Debt | 517,013 |
| Net Cash | 51.17M |
| Net Cash Per Share | $0.79 |
| Equity (Book Value) | 84.66M |
| Book Value Per Share | 1.31 |
| Working Capital | 80.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.61 million and capital expenditures -$115,730, giving a free cash flow of -$50.73 million.
| Operating Cash Flow | -50.61M |
| Capital Expenditures | -115,730 |
| Free Cash Flow | -50.73M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 92.66%, with operating and profit margins of -51.43% and -41.24%.
| Gross Margin | 92.66% |
| Operating Margin | -51.43% |
| Pretax Margin | -44.45% |
| Profit Margin | -41.24% |
| EBITDA Margin | -50.71% |
| EBIT Margin | -51.43% |
| FCF Margin | n/a |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.66% |
| Shareholder Yield | -15.66% |
| Earnings Yield | -4.34% |
| FCF Yield | -12.27% |
Analyst Forecast
The average price target for CorMedix is $15.14, which is 147.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.14 |
| Price Target Difference | 147.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 48.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2:1.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.2:1 |
Scores
CorMedix has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | n/a |